Journal
FUTURE CARDIOLOGY
Volume 17, Issue 5, Pages 769-777Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fca-2020-0150
Keywords
atherosclerosis; cardiovascular disease; inclisiran; LDL-cholesterol; PCSK9; siRNA
Categories
Funding
- Imperial NIHR Biomedical Research Centre
Ask authors/readers for more resources
Inclisiran is a siRNA inhibiting hepatic PCSK9 synthesis. As a first-in-class therapy, inclisiran has been assessed within the ORION trial program for its low-density lipoprotein cholesterol (LDL-C) lowering efficacy and clinical safety. Phase II and III trials have shown that inclisiran lowers LDL-C by about 50% with an infrequent dosing schedule in patients with established atherosclerotic cardiovascular disease and those at high risk, including patients with heterozygous familial hypercholesterolemia. Ongoing Phase III trials will provide evidence on longer-term safety and effectiveness, and inclisiran's efficacy in patients with homozygous familial hypercholesterolemia. Furthermore, the ORION-4 trial will assess inclisiran's impact on cardiovascular outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available